Biotechnology giant Biogen Inc., valued at $68 billion, has drawn takeover interest from Merck & Co. and Allergan PLC. The interest raises the possibility of another huge deal in the health-care industry, according to MarketWatch reports.
Company insiders said both Merck and Allergan have each sounded out Biogen on the possibility of a takeover. The communications were informal and preliminary, and they may not result in a deal—in part because Biogen may not be interested, they added.
Read the MarketWatch report